This report is prepared for the Warsaw Stock Exchange SA within the framework of the Analytical Coverage Support Program. 3.0. This is an excerpt from the Polish version of DM BOŚ SA’s research.
We add Voxel’s shares to the long side of our monthly portfolio.
Voxel is the company for which we prepare reports for the Warsaw Stock Exchange SA within the framework of the Analytical Coverage Support Program 3.0. Rationale: We expect the Company’s 2Q23 financials to be higher yoy not only due to last year’s low base effect (EBITDA at PLN 18 million, NI at PLN 5 million in 2Q22), but also on the back of rising volumes of diagnostic services performed (we assume a qoq growth) coupled with materially higher prices of medical procedures (by 20%- 40%).
We expect a yoy improvement of Vito-Med’s hospital’s performance resulting from restructuring (from February revenues have been on the rise) with better results of Scanix (significantly higher profitability already in 1Q23).
We add Voxel’s shares to the long side of our monthly portfolio.
Voxel is the company for which we prepare reports for the Warsaw Stock Exchange SA within the framework of the Analytical Coverage Support Program 3.0. Rationale: We expect the Company’s 2Q23 financials to be higher yoy not only due to last year’s low base effect (EBITDA at PLN 18 million, NI at PLN 5 million in 2Q22), but also on the back of rising volumes of diagnostic services performed (we assume a qoq growth) coupled with materially higher prices of medical procedures (by 20%- 40%).
We expect a yoy improvement of Vito-Med’s hospital’s performance resulting from restructuring (from February revenues have been on the rise) with better results of Scanix (significantly higher profitability already in 1Q23).
